TB CAB
By
TB CAB
Published: June 20, 2018, 1:55 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Guidelines,
Access,
Advocacy
Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow.
Read More →
By
TB advocates,
civil society,
TB CAB
Published: May 9, 2018, 9:48 p.m.·
Tags:
Drug-resistant TB,
Guidelines,
Treatment,
Advocacy
Advocates call on WHO leadership to ensure rapid development of clear, consolidated guidelines for the diagnosis and treatment of TB.
Read More →
By
TB advocates,
civil society,
TB CAB
Published: Feb. 1, 2018, 7:59 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Guidelines,
Advocacy,
TB CAB
TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.
Read More →
By
TB CAB
Published: Aug. 17, 2017, 4:33 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Advocacy
Тhe Global TB Community Advisory Board (TB CAB) releases a position paper regarding the optimal design for future evaluation of regimens for the treatment of extensively drug-resistant TB (XDR-TB).
Read More →
By
TB advocates,
TB CAB,
Treatment Action Group
Published: Aug. 16, 2017, 4:27 p.m.·
Tags:
Diagnostics,
HIV coinfection,
TB programs,
Access,
Advocacy
TB advocates urge the Kenyan Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) to introduce a new, simple, and rapid TB test, TB LAM, which detects TB antigens in urine, and is an important tool for detecting TB in certain populations living with HIV.
Read More →
By
TB CAB
Published: March 16, 2017, 1:12 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy,
TB CAB
TB advocates stress the importance of the observational endTB study for expanding access to new treatments for multidrug-resistant TB in Peru.
Read More →
By
TB CAB
Published: Feb. 14, 2017, 6:36 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy,
TB CAB
TB advocates reiterate the important role the Ministry of Health must play in facilitating access to delamanid for Peruvians with multidrug-resistant TB.
Read More →
By
TB CAB
Published: Jan. 18, 2017, 10:34 p.m.·
Tags:
Diagnostics,
Research and development,
Advocacy
TB advocates encourage Danaher, a holdings company that recently acquired Cepheid, to prioritize the continued development of critical Cepheid products for TB.
Read More →
By
TB CAB
Published: Oct. 19, 2016, 5:51 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
TB CAB
TB advocates encourage the Ministry of Health in Peru to develop country guidance on the use of delamanid for the treatment of drug-resistant TB, a first step to facilitating access.
Read More →
By
TB CAB
Published: Sept. 1, 2016, 5:33 p.m.·
Tags:
Drug-resistant TB,
Advocacy,
TB CAB
TB advocates addressed the University of Limpopo and Sefako Makgatho Health Science University demanding the immediate release of funds for the NeXT study.
Read More →
Page 3 of 7 · Total posts: 10
←First
2
3
4
Last→